Vir Biotech earnings missed by $0.25, revenue fell short of estimates

  • Investing.com
Vir Biotech earnings missed by $0.25, revenue fell short of estimates
Credit: © Reuters.

Investing.com - Vir Biotech (NASDAQ: VIR ) reported second quarter EPS of $-1.45, $0.25 worse than the analyst estimate of $-1.20. Revenue for the quarter came in at $3.8M versus the consensus estimate of $22.42M.

Vir Biotech's stock price closed at $13.97. It is down -42.98% in the last 3 months and down -52.24% in the last 12 months.

Vir Biotech saw 0 positive EPS revisions and 7 negative EPS revisions in the last 90 days. See Vir Biotech's stock price’s past reactions to earnings here.

According to InvestingPro, Vir Biotech's Financial Health score is "great performance".

Check out Vir Biotech's recent earnings performance , and Vir Biotech's financials here.

Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar.

Drop an image here or Supported formats: *.jpg, *.png, *.gif up to 5mb

Error: File type not supported

Drop an image here or

100

Related Articles